Preferred Label : Irpagratinib;
NCIt synonyms : FGFR4 Inhibitor ABSK-011;
NCIt definition : An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor
4 (FGFR4), with potential antineoplastic activity. Upon oral administration, irpagratinib
is specifically and irreversibly binds to the cysteine residue at position 552 (Cys
552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation
and activation of receptor tyrosine kinase activity that would normally occur after
binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated
signaling and leads to the inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing
cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation,
differentiation, and survival of tumor cells. FGFR4 expression is associated with
poor prognosis. FGF19 is overexpressed by certain tumor cell types.;
UNII : X46B7JM4A8;
CAS number : 2230974-62-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2230974-62-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : ABSK 011; ABSK-011;
NCI Metathesaurus CUI : CL1794270;
Origin ID : C189047;
UMLS CUI : C5706524;
Semantic type(s)
- concept_is_in_subset
- has_target
